NASDAQ listed companies are sincerely seeking TYK2 products that can penetrate the BBB and have potential CNS indications. The specific requirements are as follows:
- Stage: PCC, IND-enabling, Phase 1 clinical trial, Phase 2 clinical trial
- Molecular entities: small molecules preferred
- Targets: TYK2
- Rights Interested: Global rights, excluding China rights
- Preferred cooperation model: Licensing
If your company is interested in this opportunity, please contact the DrugTimes BD team as soon as possible!
We will discuss in detail with you. Thank you!
Email: BD@drugtimes.cn
Please include TYK2 products in the subject line.
发布者：DrugTimes001，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 